BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009;9:247-261. [PMID: 19192962 DOI: 10.1586/14737140.9.2.247] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
2 Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 2012;5:ra24. [PMID: 22457330 DOI: 10.1126/scisignal.2002739] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 11.3] [Reference Citation Analysis]
3 Totary-Jain H, Sanoudou D, Ben-Dov IZ, Dautriche CN, Guarnieri P, Marx SO, Tuschl T, Marks AR. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J Biol Chem 2013;288:6034-44. [PMID: 23300087 DOI: 10.1074/jbc.M112.416446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
4 Cheng KY, Hao M. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells. Med Sci Monit 2017;23:2017-28. [PMID: 28446743 DOI: 10.12659/msm.901542] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
5 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
6 Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011;117:5094-5102. [PMID: 21538343 DOI: 10.1002/cncr.26165] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 12.6] [Reference Citation Analysis]
7 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
8 Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2010;10:1635-1646. [PMID: 20942634 DOI: 10.1586/era.10.146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
9 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
10 Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel T. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One 2013;8:e76136. [PMID: 24086701 DOI: 10.1371/journal.pone.0076136] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
11 Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res. 2013;190:1-20. [PMID: 22941010 DOI: 10.1007/978-3-642-16037-0_1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
12 Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52:921-929. [PMID: 20385424 DOI: 10.1016/j.jhep.2009.12.034] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 10.0] [Reference Citation Analysis]
13 Rehman G, Shehzad A, Khan AL, Hamayun M. Role of AMP-activated protein kinase in cancer therapy. Arch Pharm (Weinheim) 2014;347:457-68. [PMID: 24677093 DOI: 10.1002/ardp.201300402] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 7.6] [Reference Citation Analysis]
14 Chen YL, Yen IC, Lin KT, Lai FY, Lee SY. 4-Acetylantrocamol LT3, a New Ubiquinone from Antrodia cinnamomea, Inhibits Hepatocellular Carcinoma HepG2 Cell Growth by Targeting YAP/TAZ, mTOR, and WNT/β-Catenin Signaling. Am J Chin Med 2020;48:1243-61. [PMID: 32668963 DOI: 10.1142/S0192415X20500615] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kawahara T, Toso C, Yamaguchi K, Cader S, Douglas DN, Nourbakhsh M, Lewis JT, Churchill TA, Yagita H, Kneteman NM. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma. Liver Int 2013;33:1441-8. [DOI: 10.1111/liv.12275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Panackel C, Mathew JF, Fawas N M, Jacob M. "Immunosuppressive drugs in liver transplant: An insight.". Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.06.007] [Reference Citation Analysis]
17 Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochemical Society Transactions 2013;41:917-22. [DOI: 10.1042/bst20130034] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
18 Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, Wen WC, Chen P, Guh JH. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol. 2010;79:162-171. [PMID: 19723512 DOI: 10.1016/j.bcp.2009.08.022] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 7.4] [Reference Citation Analysis]
19 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kuo TC, Chiang PC, Yu CC, Nakagawa-Goto K, Bastow KF, Lee KH, Guh JH. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways. Biochem Pharmacol 2011;81:1136-44. [PMID: 21371443 DOI: 10.1016/j.bcp.2011.02.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
21 Peruhova M, Peshevska-sekulovska M, Panayotova G, Velikova T. Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy. Gastroenterology Insights 2021;12:283-92. [DOI: 10.3390/gastroent12030025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis. 2011;29:289-302. [PMID: 21829020 DOI: 10.1159/000327562] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
23 Villa-Cuesta E, Boylan JM, Tatar M, Gruppuso PA. Resveratrol inhibits protein translation in hepatic cells. PLoS One 2011;6:e29513. [PMID: 22242130 DOI: 10.1371/journal.pone.0029513] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
24 Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M, Hurtova M, Hardwigsen J, Calmus Y, Dumortier J. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011;17:905-913. [PMID: 21384525 DOI: 10.1002/lt.22292] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
25 Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, Tisone G, Volpes R. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int 2020;14:930-43. [PMID: 33099753 DOI: 10.1007/s12072-020-10091-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
26 Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, Calvisi DF. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology 2010;52:506-17. [PMID: 20683950 DOI: 10.1002/hep.23681] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
27 Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, Schuchmann M, Schulze-Bergkamen H. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009; 15(47): 5924-5935 [PMID: 20014456 DOI: 10.3748/wjg.15.5924] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302-S309. [PMID: 20547319 DOI: 10.1016/S1590-8658(10)60521-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
29 Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol. 2010;15:242-255. [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
30 Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol 2016; 22(27): 6114-6126 [PMID: 27468204 DOI: 10.3748/wjg.v22.i27.6114] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
31 Ponziani F, Ojetti V, Tortora A, Di Maurizio L, Purchiaroni F, Gasbarrini A. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. Expert Opin Drug Metab Toxicol 2011;7:1535-46. [PMID: 22032293 DOI: 10.1517/17425255.2011.631911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, Liu Z, Sun Q, Peng H, Chen R, Jing Y, Yang H, Mao Y, Zhang H. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. Gastroenterology. 2015;149:741-52. e14. [PMID: 25980751 DOI: 10.1053/j.gastro.2015.05.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
33 Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am. 2011;40:599-610. [PMID: 21893276 DOI: 10.1016/j.gtc.2011.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011;117:5094-5102. [PMID: 21538343 DOI: 10.002/cncr.26165] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Fornaro L, Vivaldi C, Caparello C, Sacco R, Rotella V, Musettini G, Luchi S, Baldini EE, Falcone A, Masi G. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncol. 2014;10:285-304. [PMID: 24490614 DOI: 10.2217/fon.13.181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
36 Suh SJ, Yim HJ. [Current status of molecular targeted therapies in hepatocellular carcinoma]. Korean J Gastroenterol 2013;61:136-46. [PMID: 23575232 DOI: 10.4166/kjg.2013.61.3.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 2012; 18(42): 6005-6017 [PMID: 23155330 DOI: 10.3748/wjg.v18.i42.6005] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
38 Ray EM, Sanoff HK. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocell Carcinoma 2017;4:131-8. [PMID: 29184856 DOI: 10.2147/JHC.S124366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
39 Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012; 2(5): 74-83 [PMID: 24175199 DOI: 10.5500/wjt.v2.i5.74] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
40 Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 2011;54:1199-207. [PMID: 21735472 DOI: 10.1002/hep.24529] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
41 Zhang Y, Zhang JW, Lv GY, Xie SL, Wang GY. Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells. Int J Med Sci. 2012;9:216-224. [PMID: 22408571 DOI: 10.7150/ijms.4004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
42 Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplant 2017;26:429-38. [PMID: 28195035 DOI: 10.3727/096368916X694382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
43 Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle. 2013;12:1999-2010. [PMID: 23759595 DOI: 10.4161/cc.25099] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 7.2] [Reference Citation Analysis]
44 Bian P, Hu W, Liu C, Li L. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved. Arch Biochem Biophys 2020;689:108461. [PMID: 32531316 DOI: 10.1016/j.abb.2020.108461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Keane FK, Hong TS, Zhu AX. Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Semin Radiat Oncol 2018;28:332-41. [PMID: 30309643 DOI: 10.1016/j.semradonc.2018.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
46 Jimenez RH, Boylan JM, Lee JS, Francesconi M, Castellani G, Sanders JA, Gruppuso PA. Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One 2009;4:e7373. [PMID: 19816606 DOI: 10.1371/journal.pone.0007373] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
47 Gruppuso PA, Boylan JM, Sanders JA. The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle 2011;10:1050-8. [PMID: 21389767 DOI: 10.4161/cc.10.7.15230] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
48 Tang CY, Shen A, Wei XF, Li QD, Liu R, Deng HJ, Wu YZ, Wu ZJ. Everolimus in de novo liver transplant recipients: a systematic review. Hepatobiliary Pancreat Dis Int 2015;14:461-9. [PMID: 26459721 DOI: 10.1016/s1499-3872(15)60419-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
49 De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, Cillo U. Use of Everolimus in Liver Transplantation: Recommendations From a Working Group. Transplantation. 2017;101:239-251. [PMID: 27495768 DOI: 10.1097/tp.0000000000001438] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 6.2] [Reference Citation Analysis]
50 Ang C, O'Reilly EM, Abou-Alfa GK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:225-246. [PMID: 22941024 DOI: 10.1007/978-3-642-16037-0_15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
51 Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704-713. [PMID: 22120206 DOI: 10.1016/j.jhep.2011.09.020] [Cited by in Crossref: 284] [Cited by in F6Publishing: 267] [Article Influence: 25.8] [Reference Citation Analysis]
52 Feng Z, Fan X, Jiao Y, Ban K. Mammalian target of rapamycin regulates expression of β-catenin in hepatocellular carcinoma. Hum Pathol 2011;42:659-68. [PMID: 21239045 DOI: 10.1016/j.humpath.2010.07.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
53 Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29. [PMID: 20374038 DOI: 10.1517/13543781003767418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
54 Ge YY, Shi Q, Zheng ZY, Gong J, Zeng C, Yang J, Zhuang SM. MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R. Oncotarget 2014;5:6218-28. [PMID: 25026290 DOI: 10.18632/oncotarget.2189] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]